Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Stopped no sites were regulatory ready and the SC took the study to a different group.
Conditions
- Metastatic Colon Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Metastatic Rectal Adenocarcinoma
- Stage IV Colon Cancer AJCC V8
- Stage IV Colorectal Cancer AJCC V8
- Stage IV Rectal Cancer AJCC V8
Interventions
- BIOLOGICAL: Trastuzumab
- DRUG: Trifluridine and Tipiracil Hydrochloride
- DRUG: Tucatinib
Sponsor
Academic and Community Cancer Research United
Collaborators